For its small-scale study, the researchers surveyed 25 subject matter experts from payer organizations and drugmakers. Qualitative interviews were also used.
Value-based contracts, also known as outcomes-based contracting, typically involve a payer agreeing to pay more for a drug that is effective and less if it is not.
Of the 25 respondents, just one manufacturer and four payers said they had not explored or negotiated value-based contracts.
The study also found that more than 70 percent of the value-based contracts negotiated between 2014 and 2017 were not publicly disclosed.
While value-based contracting is emerging as more common, it takes a lot of effort to negotiate a contract, according to the drugmaker and payer respondents. Respondents reported that early talks translated to a signed contract 33 percent of the time for drugmakers and 60 percent of the time for payers.
“This study reveals that the majority of value-based payment arrangements are not publicly disclosed, which could underestimate their true prevalence and impact. Given the effort required to implement a VBA, future arrangements would likely benefit from a framework or other evaluative tool to help assess VBA pursuit desirability and guide the negotiation and implementation process,” the study authors said.
More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Drugmakers are treating patients, providers ‘like piggy banks,’ AHA chief says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
